Biotech Values

[DewDiligence]

Voting in HCV survey in #msg-72378069 (9 votes cast):

Q: In treatment-naive genotype-1a patients, what is the worst-case
SVR rate you expect in the first credible trial testing two direct-acting
antiviral agents without interferon or ribavirin?

a) >90%: 0%
b) 80-90%: 22%
c) 65-80%: 22%
d) 50-65%: 44%
e) <50%: 11%

The distribution of responses seems reasonable (I voted for d) ), but I’m surprised that there was not more interest in this survey.